Phaseline

Companies › Krystal Biotech

Krystal Biotech: clinical trials, targets and expected readouts

7 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 3; Other, Oncology, Metabolic and endocrine, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KB803
Replication-defective, non-integrating HSV-1 expressing human collagen VII protein
COL7A1Phase 3Dystrophic Epidermolysis BullosaDec 2026
KB407
Replication-defective HSV-1 expressing full-length human CFTR
CFTRPhase 1Cystic FibrosisDec 2026
KB408
Replication-defective HSV-1 vector expressing full-length human SERPINA1
SERPINA1Phase 1Alpha 1-Antitrypsin DeficiencyDec 2026
KB801
Replication-defective, non-integrating HSV-1 vector delivering human nerve growth factor (
NGFPhase 1Neurotrophic KeratitisDec 2026
KB707
Genetically modified oncolytic herpes simplex virus type 1 (oHSV-1)
–Phase 1Lung Cancer, Non-small Cell; CancerFeb 2027
KB301
Replication-incompetent, non-integrating HSV-1 vector expressing human type III collagen
COL3Phase 1Skin RoughnessMay 2029
KB304
HSV-1 vector delivering human collagen (COL3) and elastin (tropoelastin) genes
COL3, ELNPhase 1Wrinkles in Decolletage–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06724900KB304Phase 1Wrinkles in DecolletageOtherJul 2025
NCT06049082KB408Phase 1Alpha 1-Antitrypsin DeficiencyMetabolic and endocrineDec 2026
NCT07016750KB803Phase 3Dystrophic Epidermolysis BullosaOtherDec 2026
NCT06999733KB801Phase 1Neurotrophic KeratitisOphthalmologyDec 2026
NCT05504837KB407Phase 1Cystic FibrosisRespiratoryDec 2026
NCT06228326KB707Phase 1Lung Cancer, Non-small CellOncologyFeb 2027
NCT05970497KB707Phase 1CancerOncologyJul 2027
NCT04540900KB301Phase 1Skin RoughnessOtherMay 2029

From the company's SEC filings

Cash and short-term investments of $912m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

COL3 (2) SERPINA1 (1) COL7A1 (1) NGF (1) CFTR (1) ELN (1)

Companies with the same targets

Vertex Pharmaceuticals Takeda Tessera Therapeutics Wave Life Sciences USA Beam Therapeutics Grifols Therapeutics Shenyang Sunshine Pharmaceutical Napo Pharmaceuticals 4D Molecular Therapeutics ReCode Therapeutics

Companies built like this

Daewoong Pharmaceutical Axogen Ascendis Pharma argenx Novadip Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.